Theresa Setter, APRN
Family · Fayetteville, NYNPI 1114135209
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.6%), food and beverage and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 74.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $2,091 and has fallen 85.4% since, to $306 in 2025. Among family clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 123 payments — averaging $43.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Merz North America, Inc.$238
- E.r. Squibb & Sons, L.L.C.$196
- Amgen$177
- Johnson & Johnson$174
- Revance Therapeutics, Inc.$158
- plus $427 from 8 others
What the payments were for
- Speaking & faculty fees$2,73852%
- Food & beverage$2,54248%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 56 | $3,931 |
| Merz North America, Inc. | 2 | $238 |
| E.r. Squibb & Sons, L.L.C. | 19 | $196 |
| Amgen | 11 | $177 |
| Johnson & Johnson | 10 | $174 |
| Revance Therapeutics, Inc. | 2 | $158 |
| Lilly USA, LLC | 7 | $124 |
| Galderma Laboratories, L.p. | 5 | $98 |
| Novartis | 3 | $56 |
| Regeneron Healthcare Solutions, Inc. | 3 | $54 |
| Incyte Corporation | 1 | $29 |
| Pfizer | 2 | $25 |
| Sanofi | 1 | $23 |
| Dermavant Sciences, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAXXIFY$143
How this compares
$5,302 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 11 | $85,476 |
| Clobetasol Propionate | 31 | $904 |
| Ketoconazole | 17 | $480 |
| Imiquimod | 20 | $348 |
| CiclopiroxCiclopirox Olamine | 11 | $233 |
| Triamcinolone Acetonide | 20 | $164 |
| Hydroxyzine Hcl | 17 | $110 |
Paid to pharmacies, not to this prescriber.
Other family in Fayetteville
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.